Page 10 - Pharma Darpan August 2021 Anniversary Issue

EXPERT REVIEW Volume -II Issue -1 August-2021

Key stakeholders for drifting the current mindset:
Academia : Academia provides the foundation for building the entire research and innovation pyramid in any country. Academia is the
source of most critical resources for innovation: talent and basic research. India's higher education system is the world's third largest in
terms of students, next to China and the United States13. Following are few suggestion based on the current deficiencies,
Improve the quality of education and infrastructure in higher education institutions (HEIs), Increase number of public institutions
offering postgraduation and PhD, Set up more national and international mobility programs to foster collaboration and sharing of
perspective, Integrate topics on entrepreneurship and innovation mindset in the curricula:
• Developing Industry ready talent: According to the India Skills Report 2020, employability or job readiness in India has remained
stagnant for the past three years at around 46% (overall average employability across all sectors). This is partially due to the
insufficient infrastructure (including funding) within the educational institutions, outdated curricula, and lack of faculty with required
experience and training. Another important factor is the disconnect between the academia and the industry14. As a result, the
students coming out of educational institutions still lack the industry relevant skills and knowledge required to be job ready. Few
programs such as
• Industry and academia collaboration initiatives to enhance curriculum and job readiness
• Industry designed training programs as a part of curriculum
• Speaker Sessions, workshops and other platforms of interaction with students
Session’s like career discovery series, job shadow programs, skilling and reskilling initiates, train the trainer program’s , companies
should come forward for internships/sponsorships/ fellowship to deserving candidates. Academia and industry collaborations are
synergistic to each other. The industry benefits from access to innovative research and talent. Academia benefits by getting the
required funding, infrastructure and mentoring (technical and commercial) support for moving the ideas from research stage towards
commercialization.

Conclusion: From vision to decision
Pharmaceutical industries biggest challenge is to translate the impact of these changes on business and operating models in a holistic
way, to adapt swiftly and decisively to disruption. The lesson from other disrupted industries is loud and clear. Pharmaceutical
companies cannot just partially adjust existing business and operating models, when the fundamental rules of engagement are
changing so dramatically. Industry-academia plays a pivotal role and they need to holistically view to mitigate the current challenges
and should embrace with newer mindset and start implementing at the earliest.
One way CEOs can prepare for the future is to set up fully independent, integrated Pharma 2030 experimental laboratories that report
directly to them. These innovation labs can: – test new archetypes that align with the company’s financial ambition, to generate more
realistic forecasts that take account of the sector’s disruption – evaluate how different archetypes could impact the way the business is
organized, and, equally importantly, determine which new organizational capabilities are needed – develop a balanced transition map
that addresses the multiple and significant risks facing the business.
Those pharmaceutical companies that manage to embrace the most appropriate archetypes, and master disruption, have the greatest
chance to deliver real value to patients, which should in turn drive their success. With this vision in mind another decade will have the
scientific and technological edifice to start developing medicines that render some of the most serious diseases from which we now
suffer curable.
References:
1. Make in India, IBEF India Pharma Outlook and Brand India
2. AIOCD, Pharmaceutical Export Promotion Council
3. ey-ficci-indian-pharma-report-2021
4. USFDA website, EY analysis
5. “US generics market - evolution of Indian players”, IQVIA, February 2019. Available at: https://www.iqvia.com/-/media/iqvia/pdfs/india/us-generics-market-evolution-of-indian-
players.pdf?_=1611209375085
6. “2019 Office of Generic Drugs Annual Report”, US FDA website, February 2020. Available at: https://www.fda.gov/drugs/generic-drugs/2019-office-genericdrugs-annual-report
7. “Biosimilars Market by Product, Manufacturing & Indication, Region – Global Forecast to 2025”, ReportLinker, March 2020. Available at https://www.reportlinker.com/p04604343/Biosimilars-Market-by-
Product-Manufacturing-Application-Global-Forecast-to.html?utm_source=GNW 9
8. B. Meher et al., “Biosimilars in India; Current Status and Future Perspectives”, J Pharm Bioallied Sci., 2019. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394151/ 10
9. “India: The emerging hub for biologics and biosimilars”, report by BIRAC, November 2019. Available at: https://birac.nic.in/webcontent/Knowledge_Paper_Clarivate_ABLE_BIO_2019.pdf 16
10.“Reviving higher education of India”, Brookings India, November 2019. Available at: https://www.think-asia.org/bitstream/handle/11540/11338/Reviving-HigherEducation-in-India-email-1.pdf?sequence=1
29 “Medical Research in India: Are We There Yet?”
11.More than 750,000 Indian students abroad in 2018”, ICEF Monitor, November 2019. Available at: https://monitor.icef.com/2019/11/more-than-750000-indianstudents-abroad-in-2018/
12.“India's Higher Education Needs a Paradigm Shift”, The Wire, February 2019. Available at: https://thewire.in/education/indias-higher-education-needs-a-paradigm-shift
13.India Skills Report 2020. Available at: https://wheebox.com/india-skills-report.htm# 58
14.IQVIA Institute, Feb 2021, IQVIA market prognosis, Sep 2020

https://aptimumbai.blogspot.com ASSOCIATION OF PHARMACEUTICAL TEACHERS OF INDIA MUMBAI-REGION 8